非小细胞肺癌中外显子14跳跃突变：生物学、临床结局及检测考量概述 - Suppr

Suppr

超能文献

Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations.

作者信息

Socinski Mark A, Pennell Nathan A, Davies Kurtis D

机构信息

AdventHealth, Orlando, FL.

Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH.

出版信息

JCO Precis Oncol. 2021 Apr 13;5. doi: 10.1200/PO.20.00516. eCollection 2021.

DOI:10.1200/PO.20.00516

PMID:34036238

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8140815/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb24/8140815/89ae8f5ada67/po-5-po.20.00516-g001.jpg

相似文献

Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations.非小细胞肺癌中外显子14跳跃突变：生物学、临床结局及检测考量概述

JCO Precis Oncol. 2021 Apr 13;5. doi: 10.1200/PO.20.00516. eCollection 2021.

MET Immunohistochemistry Should Be Avoided in Selecting Non-small-cell Lung Cancers Requiring MET Exon 14 Skipping Mutation Analysis.在选择需要进行MET外显子14跳跃突变分析的非小细胞肺癌时，应避免使用MET免疫组织化学检测。

Clin Lung Cancer. 2019 May;20(3):e418-e420. doi: 10.1016/j.cllc.2018.12.002. Epub 2018 Dec 12.

Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.MET 外显子 14 跳跃突变的非小细胞肺癌患者的管理。

Curr Treat Options Oncol. 2020 Apr 18;21(4):33. doi: 10.1007/s11864-020-0723-5.

[MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer].[非小细胞肺癌中的MET外显子14跳跃突变]

Zhongguo Fei Ai Za Zhi. 2018 Jul 20;21(7):553-559. doi: 10.3779/j.issn.1009-3419.2018.07.09.

Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.非小细胞肺癌中 MET 外显子 14 跳跃突变的分子诊断检测及临床病理意义。

Clin Lung Cancer. 2019 Jan;20(1):e123-e132. doi: 10.1016/j.cllc.2018.10.004. Epub 2018 Oct 11.

MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung.MET外显子14突变作为原发性肺肉瘤样癌常规分子分析的靶点。

Oncotarget. 2017 Jun 27;8(26):42428-42437. doi: 10.18632/oncotarget.16403.

MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life.肺癌中MET外显子14改变：外显子跳跃延长半衰期

Clin Cancer Res. 2016 Jun 15;22(12):2832-4. doi: 10.1158/1078-0432.CCR-16-0229. Epub 2016 Mar 23.

Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With Exon 14 Skipping.韩国跳过外显子 14 的非小细胞肺癌患者的特征和临床结局。

In Vivo. 2020 May-Jun;34(3):1399-1406. doi: 10.21873/invivo.11920.

Novel MET exon 14 skipping analogs characterized in non-small cell lung cancer patients: A case study.新型 MET 外显子 14 跳跃模拟物在非小细胞肺癌患者中的特征：案例研究。

Cancer Genet. 2021 Aug;256-257:62-67. doi: 10.1016/j.cancergen.2021.04.005. Epub 2021 Apr 16.

A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.在东亚人群中，与其他驱动基因突变相比，对携带 MET 外显子 14 跳跃突变的肺癌患者的临床结局进行全面分析。

Lung Cancer. 2017 Jan;103:82-89. doi: 10.1016/j.lungcan.2016.12.001. Epub 2016 Dec 5.

引用本文的文献

Adding Docetaxel to Tepotinib to Overcome Oligoprogression in MET Exon 14 Skipping-Mutated NSCLC When Local Therapy Is Unfeasible: A Case Report.当局部治疗不可行时，在替泊替尼中加入多西他赛以克服MET外显子14跳跃突变的非小细胞肺癌中的寡进展：一例报告

Case Rep Oncol Med. 2025 Aug 19;2025:4483379. doi: 10.1155/crom/4483379. eCollection 2025.

Treatment of Leptomeningeal Disease with Tepotinib in a Patient with Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Presenting with Extensive Metastasis Involving Duodenum.用替泊替尼治疗一名患有MET外显子14跳跃突变的肺腺癌患者的软脑膜疾病，该患者出现广泛转移，累及十二指肠。

Reports (MDPI). 2025 Jun 18;8(2):96. doi: 10.3390/reports8020096.

MET Exon 14 Skipping Mutations in Lung Cancer: Clinical-Pathological Characteristics and Immune Microenvironment.肺癌中MET外显子14跳跃突变：临床病理特征与免疫微环境

Curr Oncol. 2025 Jul 14;32(7):403. doi: 10.3390/curroncol32070403.

Exploring cellular plasticity and resistance mechanisms in lung cancer: Innovations and emerging therapies.探索肺癌中的细胞可塑性和耐药机制：创新与新兴疗法

J Pharm Anal. 2025 May;15(5):101179. doi: 10.1016/j.jpha.2024.101179. Epub 2025 Jan 3.

Targeting c-MET Alterations in Cancer: A Review of Genetic Drivers and Therapeutic Implications.靶向癌症中的c-MET改变：遗传驱动因素与治疗意义综述

Cancers (Basel). 2025 Apr 29;17(9):1493. doi: 10.3390/cancers17091493.

Analytical and Clinical Validation of Solo-Test Driver: A Targeted Amplicon-Based NGS Test-System for FFPE and cfDNA Analysis in Clinical Oncology Setting.Solo-Test Driver的分析与临床验证：一种基于靶向扩增子的二代测序检测系统，用于临床肿瘤学环境中福尔马林固定石蜡包埋组织（FFPE）和游离DNA（cfDNA）分析

J Clin Lab Anal. 2025 Mar;39(6):e70008. doi: 10.1002/jcla.70008. Epub 2025 Mar 8.

Real world experience with MET inhibitors in MET exon 14 skipping mutated non-small cell lung cancer: largest Indian perspective.MET外显子14跳跃突变型非小细胞肺癌中MET抑制剂的真实世界经验：最大的印度视角。

Discov Oncol. 2025 Mar 8;16(1):286. doi: 10.1007/s12672-025-01864-1.

Advances in clinical research of MET exon 14 skipping mutations in non-small cell lung cancer.非小细胞肺癌中MET外显子14跳跃突变的临床研究进展

J Cancer Res Clin Oncol. 2025 Feb 12;151(2):78. doi: 10.1007/s00432-025-06115-y.

A universal immunohistochemistry analyzer for generalizing AI-driven assessment of immunohistochemistry across immunostains and cancer types.一种通用免疫组织化学分析仪，用于推广人工智能驱动的跨免疫染色和癌症类型的免疫组织化学评估。

NPJ Precis Oncol. 2024 Dec 3;8(1):277. doi: 10.1038/s41698-024-00770-z.

Application of integrin subunit genes in pancreatic cancer and the construction of a prognosis model.整合素亚基基因在胰腺癌中的应用及预后模型的构建

J Gastrointest Oncol. 2024 Oct 31;15(5):2286-2304. doi: 10.21037/jgo-24-612. Epub 2024 Oct 29.

本文引用的文献

Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non-Small-Cell Lung Cancer Using a Decision Analytic Model.使用决策分析模型比较下一代测序与单基因检测在检测转移性非小细胞肺癌基因组改变中的经济影响

JCO Precis Oncol. 2019 Dec;3:1-9. doi: 10.1200/PO.18.00356.

Exon 14-altered Lung Cancers and MET Inhibitor Resistance.外显子 14 改变的肺癌和 MET 抑制剂耐药性。

Clin Cancer Res. 2021 Feb 1;27(3):799-806. doi: 10.1158/1078-0432.CCR-20-2861. Epub 2020 Nov 10.

Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14-skipping mutation: A series of 6 cases.携带MET外显子14跳跃突变的非小细胞肺癌对免疫治疗的持久反应：6例病例系列

Lung Cancer. 2020 Dec;150:21-25. doi: 10.1016/j.lungcan.2020.09.008. Epub 2020 Sep 16.

Capmatinib in Exon 14-Mutated or -Amplified Non-Small-Cell Lung Cancer.卡马替尼治疗外显子 14 突变或扩增的非小细胞肺癌。

N Engl J Med. 2020 Sep 3;383(10):944-957. doi: 10.1056/NEJMoa2002787.

The Effect of Advances in Lung-Cancer Treatment on Population Mortality.肺癌治疗进展对人群死亡率的影响。

N Engl J Med. 2020 Aug 13;383(7):640-649. doi: 10.1056/NEJMoa1916623.

Top-level gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosis.高水平基因拷贝数增加定义了一种预后不良的低分化肺腺癌亚型。

Transl Lung Cancer Res. 2020 Jun;9(3):603-616. doi: 10.21037/tlcr-19-339.

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.特泊替尼联合吉非替尼治疗既往 EGFR 抑制剂治疗后出现 MET 过表达或扩增的 EGFR 突变型非小细胞肺癌患者：一项开放标签、Ib/II 期、多中心、随机试验（INSIGHT 研究）。

Lancet Respir Med. 2020 Nov;8(11):1132-1143. doi: 10.1016/S2213-2600(20)30154-5. Epub 2020 May 29.

Tepotinib in Non-Small-Cell Lung Cancer with Exon 14 Skipping Mutations.特泊替尼治疗伴有外显子 14 跳跃突变的非小细胞肺癌。

N Engl J Med. 2020 Sep 3;383(10):931-943. doi: 10.1056/NEJMoa2004407. Epub 2020 May 29.

Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.在 ALEX 研究中，未经治疗的晚期 ALK 阳性非小细胞肺癌患者的更新总生存和最终无进展生存数据。

Ann Oncol. 2020 Aug;31(8):1056-1064. doi: 10.1016/j.annonc.2020.04.478. Epub 2020 May 11.

MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis.非小细胞肺癌中的MET癌基因：MET失调机制及靶向HGF/c-Met轴的药物

Onco Targets Ther. 2020 Mar 25;13:2491-2510. doi: 10.2147/OTT.S231257. eCollection 2020.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验